Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 May;20 Suppl 5(0 5):66-75.
doi: 10.1111/1469-0691.12570.

Where does a Staphylococcus aureus vaccine stand?

V G Fowler Jr  1 , R A Proctor
Affiliations
Review

Where does a Staphylococcus aureus vaccine stand?

V G Fowler Jr et al. Clin Microbiol Infect. 2014 May.

Abstract

In this review, we examine the current status of Staphylococcus aureus vaccine development and the prospects for future vaccines. Examination of the clinical trials to date show that murine models have not predicted success in humans for active or passive immunization. A key factor in the failure to develop a vaccine to prevent S. aureus infections comes from our relatively limited knowledge of human protective immunity. More recent reports on the elements of the human immune response to staphylococci are analysed. In addition, there is some controversy concerning the role of antibodies for protecting humans, and these data are reviewed. From a review of the current state of understanding of staphylococcal immunity, a working model is proposed. Some new work has provided some initial candidate biomarker(s) to predict outcomes of invasive infections and to predict the efficacy of antibiotic therapy in humans. We conclude by looking to the future through the perspective of lessons gleaned from the clinical vaccine trials.

Keywords: Biomarker; Staphylococcus aureus; outcome; protective immunity; review; vaccine.

PubMed Disclaimer

Figures

Figure
Figure
Abbreviations MΦ = macrophage; PSM = phenol soluble modulins; IL = interleukin; TGF-β = transforming growth factor-β; Th17 = T helper 17 cells; MAb = monoclonal antibody; V710 = IsdB antigen used in Merck Vaccine trail; C’ = complement; SAE = Staphylococcus aureus enterotoxin E; RORγτ = retinoid-related orphan receptor gamma; STAT3 = signal transducer and activator of transcription 3; Hla = α-toxin; TSST-1 = toxic shock syndrome toxin –1; Luk = leukocidin; PVL = Panton-Valentine Leukocidin (two component toxin made up of LukS-PV and LukF-PV); IFN-γ = interferon gamma
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA. 2007;298:1763–1771. - PubMed
    1. Fowler VG, Allen KB, Moreira ED, et al. Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial. JAMA. 2013;309:1368–1378. - PubMed
    1. Koch K, Nørgaard M, Schønheyder HC, et al. Effect of socioeconomic status on mortality after bacteremia in working-age patients. A Danish population-based cohort study. PLoS One. 2013;8:e70082. - PMC - PubMed
    1. Jung WJ, Kang YA, Park MS, et al. Prediction of methicillin-resistant Staphylococcus aureus in patients with non-nosocomial pneumonia. BMC Infect Dis. 2013;13:370. - PMC - PubMed
    1. Su CH, Chang SC, Yan JJ, Tseng SH, Chien LJ, Fang CT. Excess mortality and long-term disability from healthcare-associated Staphylococcus aureus infections: a Population-Based Matched Cohort Study. PLoS One. 2013;8:e71055. - PMC - PubMed

Publication types

MeSH terms

Substances